Literature DB >> 4029012

Effect of renal function and dialysis on temocillin pharmacokinetics.

J Boelaert, R Daneels, M Schurgers, G Mellows, A J Swaisland, A M Lambert, H W Van Landuyt.   

Abstract

Temocillin pharmacokinetics in renal impairment were investigated following an intravenous bolus injection of 15 mg/kg. The 28 patients were divided into 5 groups of varying renal function, from normal to uraemic [including a group being treated with haemodialysis and a group on continuous ambulatory peritoneal dialysis (CAPD)]. The distribution of temocillin into the tissues was not affected by renal dysfunction. Uraemia as compared to normal renal function resulted in a 4.3-fold decrease in temocillin clearance and a 3.1-fold decrease in urinary recovery over 24 hours, as well as a 5- and 3.7-fold increase in the beta half-life and the area under the curve (AUC), respectively. Haemodialysis doubled the serum clearance and halved the beta half-life of temocillin in the uraemic subject, but CAPD over 24 hours eliminated only 8% of the temocillin dose, resulting in a minimal change in pharmacokinetics. Temocillin dosage adjustments in renal failure are proposed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029012     DOI: 10.2165/00003495-198500295-00023

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

1.  Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function.

Authors:  A Leroy; G Humbert; J P Fillastre; F Borsa; M Godin
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

2.  BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors:  B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

3.  The pharmacokinetics of temocillin in patients with normal and impaired renal function.

Authors:  J Boelaert; R Daneels; M Schurgers; A M Lambert; H W Van Landuyt; G Mellows; J Wolf; A J Swaisland
Journal:  J Antimicrob Chemother       Date:  1983-04       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.